INFLAMMATION, SUBSTANCE USE, SYMPTOMS, AND COGNITION IN PHASE 1 OF THE CLINICAL ANTIPSYCHOTIC TRIALS OF INTERVENTION EFFECTIVENESS STUDY

被引：0
|
作者：
Miller, Brian [1 ]
Buckley, Peter [1 ]
McEvoy, Joseph [1 ]
机构：
[1] Augusta Univ, Augusta, GA USA
来源：
SCHIZOPHRENIA BULLETIN | 2017年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
175.3
引用
收藏
页码：S89 / S90
页数：2
相关论文
共 50 条
  • [41] Antipsychotic drug use and associations with neuropsychiatric symptoms in persons with impaired cognition: a cross-sectional study
    Kuronen, Marja
    Kautiainen, Hannu
    Karppi, Pertti
    Hartikainen, Sirpa
    Koponen, Hannu
    NORDIC JOURNAL OF PSYCHIATRY, 2016, 70 (08) : 621 - 625
  • [42] Life Satisfaction Among Individuals With Schizophrenia in the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) Study
    Fervaha, Gagan
    Agid, Ofer
    Takeuchi, Hiroyoshi
    Foussias, George
    Remington, Gary
    AMERICAN JOURNAL OF PSYCHIATRY, 2013, 170 (09) : 1061 - 1062
  • [43] Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?
    Citrome, L.
    Stroup, T. Scott
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (08) : 933 - 940
  • [44] The Impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on Prescribing Practices: An Analysis of Data From a Large Midwestern State
    Berkowitz, Rachel L.
    Patel, Urvashi
    Ni, Quanhong
    Parks, Joseph J.
    Docherty, John P.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (04) : 498 - 503
  • [45] Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
    Hermes, Eric D. A.
    Sokoloff, Daniel
    Stroup, T. Scott
    Rosenheck, Robert A.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (04) : 526 - 532
  • [46] The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development
    Stroup, TS
    McEvoy, JP
    Swartz, MS
    Byerly, MJ
    Glick, ID
    Canive, JM
    McGee, MF
    Simpson, GM
    Stevens, MC
    Lieberman, JA
    SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 15 - 31
  • [47] The estimand framework and its application in substance use disorder clinical trials: a case study
    Roydhouse, Jessica K.
    Floden, Lysbeth
    Tomko, Rachel L.
    Gray, Kevin M.
    Bell, Melanie L.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2021, 47 (06) : 658 - 663
  • [48] Prediction of quality of life in schizophrenia using machine learning models on data from clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia
    Beaudoin, M.
    Potvin, S.
    Hudon, A.
    Giguere, C. -E.
    Dumais, A.
    EUROPEAN PSYCHIATRY, 2021, 64 : S157 - S157
  • [49] Use of placebos in Phase 1 preventive HIV vaccine clinical trials
    Huang, Yunda
    Karuna, Shelly T.
    Janes, Holly
    Frahm, Nicole
    Nason, Martha
    Edlefsen, Paul T.
    Kublin, James G.
    Corey, Lawrence
    McElrath, M. Juliana
    Gilbert, Peter B.
    VACCINE, 2015, 33 (06) : 749 - 752
  • [50] Effectiveness of N-acetylcysteine in Treating Clinical Symptoms of Substance Abuse and Dependence: A Meta-analysis of Randomized Controlled Trials
    Chang, Chung-Ting
    Hsieh, Pei-Ju
    Lee, Hsin-Chien
    Lo, Chun-Hong
    Tam, Ka-Wai
    Loh, El-Wui
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2021, 19 (02) : 282 - 293
12345